Anzeige
Mehr »
Login
Montag, 20.01.2020 Börsentäglich über 12.000 News von 622 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1T9L2 ISIN: US29428V1044 Ticker-Symbol: EPE 
Tradegate
17.01.20
18:04 Uhr
24,000 Euro
+1,000
+4,35 %
1-Jahres-Chart
EPIZYME INC Chart 1 Jahr
5-Tage-Chart
EPIZYME INC 5-Tage-Chart
RealtimeGeldBriefZeit
24,400
24,600
19.01.
24,000
24,200
17.01.

Aktuelle News zur EPIZYME Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
EPIZYME Aktie jetzt für 4€ handeln
06.01.Epizyme to sell additional $50M of stock to Royalty Pharma; shares down 7%8
06.01.Epizyme, Inc. - 8-K, Current Report1
26.12.19Epizyme (EPZM) Shares Soar on Lead Candidate's Progress9
19.12.19Epizyme's sarcoma drug sails through FDA panel with unanimous vote11
19.12.19Epizyme files U.S. application for tazemetostat for follicular lymphoma7
18.12.19Tox issues? Check. Questionable efficacy data? Check. OK to market? ODAC says check that box for Epizyme3
18.12.19Epizyme up 12% after advisory committee nod on tazemetostat1
18.12.19FDA advisory committee backs Epizyme's tazemetostat1
18.12.19What To Expect From Epizyme's Tazemetostat Adcom Meeting2
18.12.19Benzinga Pro's Top 5 Stocks To Watch For Wed., Dec. 18, 2019: UPS, MU, EPZM, SLDB, XXII8
18.12.19Epizyme shares halted for today's Ad Com review-
17.12.19FDA's in-house review offers bleak assessment of Epizyme's tazemetostat - but win or lose this cancer drug may still have a future2
17.12.19FDA raises doubts about benefits of Epizyme's cancer drug ahead of AdComm3
16.12.19FDA Ad Com this week for Epizyme's tazemetostat for epitheloid sarcoma1
15.12.19The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week10
08.12.19At The ASH 2019 Annual Meeting: AXLA, CBMG, SRRA, EPZM, STOK...2
07.12.19Epizyme's tazemetostat shows positive action in mid-stage FL study3
05.12.19Epizyme +2.6% as Morgan Stanley joins other bulls3
04.12.19Epizyme Announces FDA Committee Review of Tazemetostat NDA4
02.12.19Epizyme down 6% ahead of tazemetostat Ad Com review2
Seite:  Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1